Form 4: Third Harmonic Bio CEO Awarded Stock Options and Restricted Stock Units

Third Harmonic Bio's CEO, Natalie Holles, received stock options for 400,000 shares and 50,000 restricted stock units as part of the company's annual equity refresh.

Summary

• Natalie Holles, CEO of Third Harmonic Bio, was granted stock options for 400,000 shares and 50,000 restricted stock units.
• The grants were approved by the board on December 17, 2024, as part of the annual equity refresh program.
• The effective grant date for both the options and restricted stock units is January 15, 2025.
• The stock options have an exercise price of $6 and vest monthly over four years, starting February 15, 2025.
• The restricted stock units vest annually over four years, starting February 15, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The equity grants align the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.
• The grants are part of a regular annual process, indicating a consistent approach to executive compensation.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of the company's stock price.
• The vesting schedule requires continued service, which could be a risk if the CEO were to leave the company.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedules of the equity grants.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech industry, often including stock options and restricted stock units.
• The vesting schedules described are typical for such grants, with monthly vesting for options and annual vesting for restricted stock units.
• The specific amounts and terms of the grants would need to be compared to similar companies to determine if they are in line with industry norms.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the CEO to increase the company's value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity grants, executive compensation, CEO, Third Harmonic Bio, vesting